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Summary
Objective: As crystals may contribute to inflammation in osteoarthritis (OA), it is hypothesized that colchicine may have symptom/disease
modifying effects in OA. The objective of this study was to evaluate the symptomatic benefit of addition of colchicine to a regimen of
intraarticular steroids and piroxicam in patients with knee OA with inflammation.
Design: 39 patients with OA of the knee with persisting inflammation, despite at least 2 weeks of piroxicam, were subjected to intraarticular
steroid injection and randomly assigned to receive colchicine 0.5 mg twice daily or placebo in a randomized, double blind, placebo-controlled
trial over 5 months.
Results: VAS for index knee pain (VAS-pain) and total KGMC score (a modified WOMAC index) at 16 and 20 weeks were significantly better
in the colchicine group than the corresponding scores in controls. The benefit persisted on multivariate analysis at 16 weeks (Hotellings
T2=18.6, F5,33=3.3154, P=0.015). The proportion of patients who had 30% or greater response at 16 weeks was significantly higher in the
colchicine group in VAS-pain (69% vs 15%) and total KGMC scores (74% vs 45%) and the significance persisted on combined analysis using
Mantel-Haenszel test (M-H Risk=5.9, 95% C.I.: 2.08 to 16.73). At 20 weeks, benefit of colchicine therapy was seen on pooled analysis only
(M-H risk=3.71, 95% C.I.: 1.07=8.02).
Conclusion: The addition of colchicine produced significantly greater symptomatic benefit at 16 and 20 weeks than intraarticular steroid and
piroxicam alone in patients with knee OA with inflammation. © 2002 OsteoArthritis Research Society International
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Acute flares of inflammation are accepted as a component
in the course of most patients with advanced sympto-
matic osteoarthritis (OA)1. Multiple factors contribute to this
inflammation, with crystals especially calcium pyrophos-
phate dihydrate (CPPD) crystals being one of the factors
needing consideration. CPPD crystal deposition has been
considered variously to have either no relationship to OA2,
or to favor its development3, or to contribute to its inflam-
matory component4, or to result from OA5. Whether a
cause or effect, these crystals offer the potential for inflam-
mation1 and, thereby, development of symptoms and
worsening of OA. We hypothesized that colchicine, a drug
proven to prevent crystal-induced inflammation in gout,
could have symptom modifying effects in patients with OA
with inflammation.
A preliminary open study of colchicine in patients with
OA of the knee with inflammation and demonstrable CPPD
crystals in synovial fluid on polarized light microscopy
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the polarized light microscopic method of crystal identifica-
tion may underestimate the crystalline disease7, it was
decided to undertake the present study in patients with
clinical signs of inflammation irrespective of whether or not
crystals were identified. Since colchicine in low doses is not
known to suppress inflammation rapidly, the initial suppres-
sion of inflammation was carried out with intraarticular
steroids and piroxicam in both branches of the study, and
thereafter colchicine was given in double-blind randomized
fashion. This is the first report of a randomized placebo-
controlled trial of colchicine in OA with inflammation.Patients and methods
PATIENTS
Patients were between 40 to 75 years of age, and
fulfilled the 1986 American College of Rheumatology (ACR)
criteria for knee OA8, without clinical or radiological
evidence of rheumatoid arthritis or other immunological
diseases, renal/hepatic diseases, allergies or contraindica-
tions to the use of piroxicam, colchicine and intraarticular
steroids. All the 39 patients included in the trial had a
negative rheumatoid factor, serum uric acid <6.5 mg/dl,
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hemoglobin of 8 gm/dl, total leukocyte count> 3500/cmm,
serum creatinine ≤1.3 mg/dl and transaminases <45 IU/l.
All patients had at least two of the following four clinical
signs of inflammation: warmth over the joint area (29
patients), joint margin tenderness (in 34 patients), synovial
effusion (in 38 patients), and soft tissue swelling around the
knee (in 38 patients). Concomitant therapy with other
NSAIDs and corticosteroids was not permitted.PROTOCOL
The ethical committee of our institution cleared the entire
trial protocol. All patients gave a written informed consent
before inclusion. Patients with persistent clinical signs of
inflammation despite at least 2 weeks of piroxicam and
satisfying other eligibility criteria were enrolled. Clinical
assessments were made on day 0, and at weeks 4, 8, 12,
16 and 20. Clinical assessment consisted of physical
examination, signs of inflammation, and primary and sec-
ondary measures of disease assessment. A specially
trained examiner (KM) performed all the clinical assess-
ments. All investigators including the examiner had no
knowledge of the patient’s treatment assignments.
X-rays of both knees in standard anteroposterior and
lateral projections were done and were assessed indepen-
dently by a rheumatologist and a radiologist. Articular
cartilage calcification (chondrocalcinosis) was seen in 38%,
although, no meniscal calcification could be identified.
Biochemical evaluation and urinalysis were performed at
baseline and at 20 weeks. Synovial fluid was aspirated
from the more severely involved knee under aseptic
conditions. The synovial fluid examination showed a
mean protein of 2.5 gm/dl. CPPD crystals could be demon-
strated in 74% of patients using routine and compensated
polarized light microscopy.
Adverse events were recorded in an open format for new
problems and a VAS for abdominal problems. The reasons
for withdrawal were pre-specified as lack of efficacy, not
willing to continue, inability to come, non-compliance,
serious systemic toxic effects, or erroneous inclusion.TREATMENT
On screening, all eligible patients received piroxicam
20 mg twice daily for 2 days and then once daily for at least
2 weeks before the start of study medication. On enrolment
a knee joint aspiration was performed followed by injection
of depot preparation of methyl prednisolone acetate 80 mg
in the more severely involved knee. The patients were then
randomized on a 1:1 scheme to receive either 0.5 mg of
colchicine twice daily or placebo, while continuing piroxi-
cam 20 mg once daily compulsorily for 8 weeks and then as
required by the patient. The study drug was supplied in
bottles as capsules containing starch and colchicine 0.5 mg
per capsule. The placebo was supplied in an identical
capsule that contained starch alone. A person not involved
in the trial performed randomization in blocks of four, and
the randomization code was sealed in individual envelopes
until the completion of the study. In all cases the code
remained unbroken for the duration of the study.STUDY END POINTS
The primary efficacy end points were 30% improvement
in responder rate in Visual Analog Scale for index knee pain(VAS-pain) and total King George’s Medical College
(KGMC) scale9 (a modified WOMAC index10). Secondary
end points were similar improvements in Doyle’s index11,
modified Clinical Health Assessment Questionnaire (Mod
HAQ), Patients’ health satisfaction score, and physicians’
global assessment of response to treatment.
All VAS scales were recorded on a 15 cm scale. The
ModHAQ is a non-validated modification of a scale used at
All India Institute of Medical Sciences, New Delhi and
ClinHAQ scale12. All scores were totalled. The KGMC scale
has been validated against Western Ontario and McMaster
University Osteoarthritis Index (WOMAC)9. It primarily con-
sists of WOMAC scale for pain, WOMAC scale for stiffness
and a modified WOMAC function scale to suit Indian
conditions and activities. New activities included in KGMC
scale are squatting for toilet, getting in/out cycle/auto
rikshaw, sitting in lotus position and daily prayer. Activities
deleted from the original WOMAC scale are bending to
floor, getting in/out of car, lying in bed, sitting, getting on/off
toilet, light domestic duty and taking off/putting on socks.STATISTICAL ANALYSIS
An ‘intention-to-treat analysis’ was used, and for patients
who dropped out, their last assessment scores were
utilized for analysis (last-observation-carried-forward). A
comparative analysis was done between the assessment
variables at various visits in both the groups by the paired
t test. An intergroup comparative analysis was done
between the assessment variables at various visits in both
groups by analysis of variance (ANOVA). An adjustment for
baseline values was done using analysis of covariance
(ANCOVA). To take into account the interdependence
among the assessment variables, a multivariate analysis
was performed using Hotelling’s T2-statistics. The pro-
portion of patients in both the groups showing 30% or more
response (pre-decided at the start of study), at 16 weeks
and 20 weeks in the various variables were compared
using either Pearson’s Chi-square test or Fisher’s exact
test for both primary end points. A Mantel Haesznel Test
statistic was used to combine odds ratio across the two
2×2 tables. All statistical analysis was carried out using
BMDP (Version 7.1) statistical software.
A minimum sample size of 36 patients was calculated on
the assumption that a 30% improvement rate would be
25% in the control group and 75% in the colchicine treated
group, with a power of test of 80%, at 95% confidence
limits.Results
The study population (N=39) consisted predominantly of
females (67%) with a mean age of 53 years and mean
duration of disease of 3.8 years (6 months to 22 years) with
majority in ARA functional class II (92%). The knee involve-
ment was generally bilateral (95%) and clinical evidence of
patellofemoral involvement was seen in 21%. The mean
erythrocyte sedimentation rate (ESR) was 51 mm/1st hour
and mean C reactive protein (CRP) was 0.7 mg/dl. Since
CRP levels were within normal limits, the increase in ESR
at least in part could be due to associated anemia.
On decoding, 19 patients were found assigned to receive
colchicine and 20 patients placebo. Baseline demographic,
radiological, biochemical, and clinical characteristics were
well matched in the two groups (Table I). Of the 19
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communicated inability to come, two were lost to follow up,
and one patient was dropped because of non-compliance.
Out of the 20 placebo assigned patients, 14 completed 5
months; one was lost to follow up, one patient was dropped
because of non-compliance, and four withdrew because of
lack of efficacy. Among the drop-outs, four of the control
and three of the study patients were positive for CPPD
crystals in joint fluid. Neither the total number nor the timing
of withdrawals was any different in the two groups. None of
the patients had a post-injection flare.EFFICACY
There was no difference at baseline between the two
groups in both primary and secondary measures of
response using univariate analysis. A multivariate analysis
using VAS for index knee pain, total KGMC scores, Doyle’s
Index, ModHAQ and NSAID intake also did not show any
difference (Hotelling T2=3.6767, F4,34=0.8446, P=0.506).
At 16 weeks (Visit 5) the mean total KGMC scores were
better in the colchicine group as compared to placebo
group (F1,37=4.63, P=0.038) The significance level
increased when scores were adjusted for baseline using
ANCOVA (F1,36=8.8, P=0.005). Similarly mean VAS for
index knee pain was significantly better in the colchicine
group as compared to placebo (F1,37=11.1, P=0.002)
which improved on adjustment for base line using ANCOVA
(F1,36=15.3, P=0.0004). However, at 20 weeks signifi-
cance levels were marginal but still significant [total KGMC
score adjusted for baseline using ANCOVA (F1,36=5.97,
P=0.02) and VAS for index knee pain adjusted for baseline
using ANCOVA (F1,36=4.0851, P=0.05)].
Among the secondary measures, Doyle’s scores did not
show any significant difference. However ModHAQ scores
showed significant differences between colchicine and
placebo groups both at 16 and 20 weeks when scores were
adjusted for baseline (P=0.0035 and P=0.01, respectively)
but not in unadjusted scores (P=0.16 and P=0.058
respectively). There was significantly less intake of NSAIDat both 16 weeks (F1,37=4.75, P=0.036) and 20 weeks(F1,37=7.22, P=0.01).
When a multivariate analysis was done using VAS
for index knee pain, total KGMC score, Doyles index,
ModHAQ and NSAID intake there was a significant differ-
ence at 16 weeks (Hotellings T2=18.6, F5,33=3.3154,
P=0.015) but not at 20 weeks (Hotellings T2=8.05,
F5,33=1.44, P=0.24).RESPONDERS RATE
The proportion of patients who achieved 30% response
in total KGMC scores and VAS for index knee pain at 16
and 20 weeks are given in Table II. At 16 weeks signifi-
cantly more patients in the colchicine group showed a 30%
or more response compared to the placebo group in VAS
for index knee (χ2111.5, P=0.0007), but borderline in total
KGMC score (χ21=3.13, P=0.06). Mantel–Haesnzel pooled
estimate across the two 2×2 tables, showed a risk of 5.95
with corresponding 95% confidence interval of 2.08 to
16.73. Since the confidence interval does not include unity
it indicates a positive correlation between colchicine treat-
ment and improvements in total WOMAC scores and VAS
for index knee pain. Although responder rate at 20 weeks
did not show statistical significance in individual variables,
the pooled estimate showed a MH risk of 3.71 with 95%
confidence interval of 1.07 to 8.02, which again did not
include unity favoring the colchicine group. The responder
rates in Doyle’s index did not achieve significance levels.
Significance levels were achieved in ModHAQ at 16 weeks
and piroxicam intake at 20 weeks.Table I
Baseline demographic and clinical characteristics of the study patients
Character Colchicine group (N=19) Control group (N=20)
Demographic characteristics
Age (years) mean±S.D. 54.4±7.9 51.5±8.2
Sex ratio (male:female) 6:13 7:13
Clinical characteristics
Duration of OA (years) (mean±S.D.) 3.6±3.1 3.9±5.1
Knee pain 19 (100%) 20 (100%)
Crepitus 19 (100%) 20 (100%)
Morning stiffness <30 min 17 (89%) 20 (100%)
Signs of inflammation 19 (100%) 20 (100%)
ARA class II 19 (100%) 17 (85%)
Biochemical characteristics
S. uric acid (mg.%) (mean±S.D.) 5.0±0.5 4.9±0.7
ESR (mm per 1st hour) (Mean±S.D.) 49.5±10 52.2±12.7
Synovial fluid analysis
CPPD crystals 15 (79%) 14 (70%)
Radiological characteristics
Osteophytes 19 (100%) 20 (100%)
Joint margin sclerosis 15 (79%) 16 (80%)
Articular cartilage calcification 8 (42%) 7 (35%)
None of the characteristics showed a statistical significance on intergroup comparison.SAFETY AND TOLERABILITY
Colchicine was well tolerated. Loose motions and dys-
peptic symptoms were the most common adverse events
encountered, but were not significantly increased in
colchicine treated patients (Table III). Significantly greater
number of patients in the control group recorded pain in
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visits) as a significant new problem as compared with
colchicine group (in eight patient visits; P value <0.0004).
The dyspepsia and loose stools observed were usually
mild, and did not require any concomitant therapy or
change in study medication.
VAS for abdominal problem decreased significantly on
all subsequent evaluations in both the groups from 12
weeks onwards, and the decrease was significantly greater
in the colchicine group as compared to control group
(P<0.02 ) at 20 weeks.
No patient died and none was hospitalized during the
study or within 30 days after receiving the last dose of the
study drug. No serious laboratory abnormality was noted in
either group. No patient withdrew because of any drug
related adverse events. Intraarticular steroid was also well
tolerated and no adverse event related to the use of
intraarticular steroid was encountered in the study.Table II
Thirty percent responder rate and confidence intervals (in parentheses)
Measures 16 weeks 20 weeks
Control Colchicine Control Colchicine
Total KGMC Scale 45 (21,69) 74 (51,96) 60 (36,84) 84 (65,100)
VAS—pain 15 (0,33) 68 (45,92) 35 (12,58) 58 (33,83)
Doyle’s Index 55 (31,79) 68 (45,92) 45 (21,69) 74 (51,96)
Health satisfaction 50 (26,74) 84 (65,100) 50 (26,74) 84 (65,100)
ModHAQ 45 (21,69) 84 (65,100) 55 (31,79) 84 (65,100)
Physicians’ global assessment 60 (36,84) 95 (85,100) 60 (36,84) 84 (65,100)
NSAID intake 20 (3,38) 53 (30,75) 20 (3,38) 63 (41,85)Table III
Adverse events/new problems
New problem % per patient visit P value
Colchicine group
(N=19)
Control group
(N=20)
Dyspeptic symptoms 8 4 0.2
Upper respiratory tract infection and fever 5 1 0.11
Increased musculoskeletal pain 8 28 0.0004
Loose motions 6 8 0.65
Other new problems 4 6 0.75
Total new problems 33 47 0.04Discussion
The addition of colchicine to intraarticular steroid and
piroxicam was well tolerated and resulted in sustained
control of symptoms in patients with OA of the knee over a
5-month period. Use of intraarticular steroid and piroxicam
alone also produced improvements in the control group;
however, these improvements were short lived. These
results confirm the trend seen in our earlier open trial in
patients with OA of the knee with signs of inflammation and
CPPD crystals in the synovial fluid6.
There are no accepted criteria for inflammation in OA.
The presence of two or more classical signs of inflamma-
tion such as warmth, synovial effusion, soft tissue swelling
and joint margin tenderness were considered as indicative
of inflammation in joint. Such inflammation is seen in 30%
of patients with OA attending our rheumatology clinic13.
Because this is a tertiary care center, the percentage is
expected to be higher than that seen at primary caresettings. CPPD crystals were demonstrated in 75% of the
study population by routine polarized light microscopy. This
is higher than the reported figures of 60% for CPPD and/or
apatite crystals by polarized light microscopy in unselected
patients with OA14. Inclusion of only the patients showing
clinical signs of inflammation could explain the higher
prevalence of crystals.
None of the study patients had involvement of atypical
joints for OA, such as, elbow, wrist or shoulder that would
suggest primary CPPD crystal deposition disease. The
patients were selected from a population of patients with a
diagnostic label of OA satisfying the ACR criteria for OA of
the knee. However, 30% of these patients also fulfilled the
definitive diagnostic criteria for CPPD crystal deposition
disease15, namely radiological chondrocalcinosis and
synovial fluid CPPD crystals by polarized light microscopy,
a finding which may suggest that CPPD crystal deposition
disease and OA may be a continuing spectrum of
presentation.
Ideally in assessing the symptom modifying effect of any
drug in OA, routine use of an analgesic or intraarticular
steroid is not advisable. Colchicine in the dose used does
not have any inherent rapid analgesic/antiinflammatory
effect, and its effect in acute pseudogout is not impressive.
At this dose colchicine is more useful in preventing rather
than treating crystal-induced inflammation. These con-
siderations led us to use intraarticular steroid and continu-
ous piroxicam (background therapy) in both the arms to
rapidly control inflammation. Intraarticular steroids in OA of
the knee are known to produce significant benefit com-
pared with placebo, although the effect appears to last for
only a few weeks16. Hence, it was expected that the use of
intraarticular steroids would not confound the outcome at
4–5 months. The study design chosen was to find the
difference that the addition of colchicine makes to the
standard treatment (piroxicam and intraarticular steroid) of
OA with inflammation. Whether this combination alone
(piroxicam and intraarticular steroid) is better than placebo
Osteoarthritis and Cartilage Vol. 10, No. 4 2510.5
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Fig. 1. Comparison of mean±standard error in both groups. A, VAS-pain; B, Mod HAQ; C, Doyle’s index; D, total KGMC scale; E, NSAID
intake. Control, – – – –; colchicine, —m—.•or piroxicam or intraarticular steroid alone has not been
assessed in this trial.
The use of intraarticular steroid plus continuous piroxi-
cam with placebo resulted in a 30% or greater improvement
in VAS for pain and total KGMC scores in 15–60% of
patients. The addition of colchicine improved these figures
to 58–84% (Table II). The 50% response rate was roughly
10–25% in the control group and 47–52% in the colchicine
group.
An unexpectedly good response in the background-
treated control group led to lower significance levels than
expected. Continued efficacy of the background therapy or
a significant regression from baseline (acute inflammatory
flare) is possible. Either way a better than expected
response in the control group would only create a bias
against the hypothesis that colchicine would be helpful in
this situation. However, the response was partly obtained at
a higher than baseline mean intake of piroxicam. Not onlywas the mean value of daily piroxicam intake significantly
higher at 20 weeks, but also the proportion of patients
requiring more than 30% increased piroxicam intake was
significantly higher—30% in the control group as compared
with 0% in the colchicine group (P<0.02). The average
monthly intake of piroxicam from 8 weeks (time until intake
of piroxicam once daily was compulsory as per protocol) to
the completion of the study was 26.9±10.5 in the colchicine
group and 32.8±15.3 in the control group (P<0.002).
Colchicine was very well tolerated and there was no
significant increase in new problems compared to placebo.
Gastrointestinal intolerance is more common with the
higher doses of colchicine required to abort an acute attack
of gout where its role is limited by appearance of side
effects17. High doses were not used in the present study.
The VAS for abdominal problem improved in both
groups and significantly greater reduction occurred in the
colchicine treated patients. This could have been due to
252 S. K. Das et al.: Colchicine in OAlesser intake of piroxicam in the colchicine group. The
good tolerance of colchicine observed in our study
correlates in general with the observed toxicity of colchicine
on long-term administration for indications like familial
Mediterranean fever and prophylaxis of gout18.
The use of colchicine to sustain the benefit obtained with
intraarticular steroids is a novel therapy for OA with inflam-
mation. Although the rationale of the study was the possible
usefulness of colchicine in crystal-induced inflammation, it
cannot be said with certainty that colchicine is effective by
way of decreasing crystal-induced inflammation only. If
colchicine does act by reducing crystal-induced inflamma-
tion and the crystal presence has relevance in the inflam-
mation amplification loop, then intraarticular steroids to
treat, and colchicine to prevent the phasic increase in
inflammation, could take care of at least one reversible
component in OA, and thereby could arrest or slow down
disease progression.References
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